NanoViricides (NYSE:NNVC) Stock Price Up 2.9% – Should You Buy?

NanoViricides, Inc. (NYSE:NNVC)’s stock price traded up 2.9% during mid-day trading on Monday . The stock traded as high as $1.12 and last traded at $1.05. Approximately 650,239 shares traded hands during trading, an increase of 25% from the average daily volume of 519,074 shares. The stock had previously closed at $1.02.

Analyst Upgrades and Downgrades

Separately, Noble Financial initiated coverage on NanoViricides in a research report on Monday, July 6th. They issued an “outperform” rating and a $6.00 price target for the company. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $6.00.

NanoViricides Trading Up 12.9%

The stock’s 50-day simple moving average is $1.39 and its 200-day simple moving average is $1.32. The firm has a market capitalization of $30.25 million, a P/E ratio of -1.65 and a beta of 1.66.

Institutional Investors Weigh In On NanoViricides

Hedge funds have recently made changes to their positions in the business. Miller Financial Services LLC purchased a new stake in shares of NanoViricides during the 4th quarter worth approximately $81,000. BlackRock Inc. bought a new position in NanoViricides during the second quarter valued at $219,000. Finally, Connective Capital Management LLC purchased a new stake in NanoViricides in the second quarter worth $256,000. 10.30% of the stock is currently owned by institutional investors.

NanoViricides Company Profile

NanoViricides, Inc is a clinical-stage biotechnology company focused on the development of novel antiviral therapies using its proprietary nanomicelle technology. The company designs polymeric, virus-targeted nanoviricides that seek to neutralize viral pathogens by binding to specific viral surface proteins and destroying their structural integrity. NanoViricides’ platform is intended to offer broad-spectrum activity against a range of enveloped viruses, positioning it as a potential solution for both existing and emerging viral threats.

The company’s pipeline includes preclinical and early clinical candidates targeting seasonal and pandemic influenza strains, as well as investigational programs for coronaviruses, hepatitis, dengue, HIV and other viruses.